The OCMX™ is pleased to announce the listing of Inmedix Inc. to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity. This Limited priced-round opportunity closes on October 31, 2020
NORMANDY PARK, WA, October 21, 2020 /24-7PressRelease/ — Inmedix is using servers to replace the massive infrastructure and low margins of traditional clinical laboratories and launching with the first accurate clinical measure of stress. Think bloodless LabCorp or Quest Diagnostics in the Microsoft Azure cloud.
Applying the cloud, Inmedix identified actionable clinical diagnostics from bloodless biomarkers (ECG, EEG, facial recognition, etc.) We begin by bringing the 5-min ECG stress testing trusted by professional sports and US Special Forces through the FDA to clinicians.
The OCMX™ is pleased to announce the listing of Inmedix Inc. to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.
The OCMX™ has spent considerable time completing its due diligence on Inmedix Inc. Corporation and concluded that there is indeed a tremendous potential for this opportunity.
The OCMX™ noted that Inmedix Inc. exhibits the main components of any solid opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.
Andrew J Holman MD, CEO/ Co-founder
Leading international expert in immune-autonomics and coined the term. Successfully sold first Inmedix patent portfolio to pharma for $10MM (30x return)
Steven Daly MS (biomedical), MBA, Chief Operating Officer
20-yr experience in Medtech funding, regulatory, QMS and launch.
Glynis Thakur, Director, Finance & Reimbursement
20+ yr experience as CEO in medical businesses (billing and reimbursement)
Daniel Austen, Manager, InmedixUk, Ltd.
20+ yr experience pharma sales and private London rheumatology clinic.
World domain expertise in the field of immuno-autonomics.
We spent 20 years and 9 human studies with <300 patients to identify the first accurate measure of autonomic nervous system (ANS) stress state. We are first/only to:
• Predict 52-wk treatment outcome in rheumatoid arthritis (RA)
• Triple RA remission by optimizing stress biology
• Independently projected by UW health economists to reduce US cost of RA care by up to $34 Billion over 10 years.
WHERE THEY ARE HEADED
Inmedix has built a scalable, reimbursed cloud platform for processing bloodless, actionable clinical diagnostics. Autoimmune disease as the first target (3800 US rheumatologists), but all of medicine is impacted by stress. Today, we treat disease. Tomorrow, we will assess and mitigate the biology of stress driving disease to excess and enhance the efficacy of current therapeutics at significantly reduced cost.
ABOUT THE OCMX™
The OCMX™ is changing how companies generate exposure in the financial marketplace and raise funds as we know it. The OCMX™ serves both public and private companies in need of market exposure during financial raises. It does this by way of connecting the relevant companies with financial institutions all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.
The OCMX™ connects investors and advisors directly with companies seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors. The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
For the original version of this press release, please visit 24-7PressRelease.com here